Onder, Halil IbrahimAktan, GulderenYuksel, HarunAvcioglu, SedatYildirim, UmranKaya, MuratTunc, Murat2024-04-242024-04-2420131080-76831557-7732https://doi.org/10.1089/jop.2012.0075https://hdl.handle.net/11468/17168Purpose: The aim of this study was to investigate the neuroprotective effect of olanzapine (OLA), an atypical antipsychotic drug, on N-methyl-D-aspartate (NMDA)-induced retinal injury. Methods: Retinal neuronal ischemia was induced by NMDA in Wistar rats. OLA was administered intraperitoneally in 2 different dosages: 2 and 12 mg/kg. At the end of 2 weeks of OLA treatment, 1 eye of each animal was enucleated for histopathologic examination. We also measured malondialdehyde (MDA) levels in retinal homogenates as a marker of ischemic injury. Results: The retinal ganglion cell (RGC) count was significantly higher in cases where we used OLA 2 mg/kg or OLA 12 mg/kg compared to the control group (P = 0.0032 and P = 0.0005, respectively). We also found that MDA was significantly reduced by OLA 2mg/kg or OLA 12 mg/kg compared to the control group (P = 0.0001 and P = 0.0001, respectively). There was no statistically significant difference between OLA 2 mg/kg or OLA 12mg/kg groups in terms of RGC count and MDA levels (P > 0.05 for all). Conclusion: Our data showed that OLA preserved RGCs from NMDA-induced retinal injury; thus, it may have potential neuroprotective effects.eninfo:eu-repo/semantics/closedAccess[No Keyword]Article294427430WOS:0003182219000112-s2.0-848805266312321575210.1089/jop.2012.0075Q2Q3